Liver Diseases  >>  tivantinib (ARQ 197)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
NCT00802555: Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Checkmark P2 data (HCC)
Jun 2012 - Jun 2012: P2 data (HCC)
Completed
1b
21
US, Europe
ARQ 197
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Cirrhosis, Hepatocellular Carcinoma
12/11
12/11
NCT01656265: Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

Completed
1
24
Japan
ARQ 197, Tivantinib
Kyowa Kirin Co., Ltd.
Advanced Hepatocellular Carcinoma
03/14
03/14
NCT02150733: Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment

Completed
1
29
US
Tivantinib
Daiichi Sankyo, Inc., Medpace, Inc.
Hepatic Impairment, Solid Tumor, Cancer
12/15
07/16

Download Options